Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

被引：6
|
作者：
Yap, Timothy A. [1 ,2 ]
Popat, Sanjay [1 ,3 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Inst Canc Res, London, England
[3] Imperial Coll London, Natl Heart & Lung Inst, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
ACQUIRED-RESISTANCE; AMPLIFICATION; INHIBITORS; MUTATIONS; CARCINOMA;
D O I：
10.1016/j.jtho.2016.10.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [21] Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
    Fujino, Toshio
    Suda, Kenichi
    Mitsudomi, Tetsuya
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 35 - 50
  • [22] Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations
    Huang, Caiwen
    Zou, Qihua
    Liu, Hui
    Qiu, Bo
    Li, Qiwen
    Lin, Yongbin
    Liang, Ying
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (04)
  • [23] MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
    Yan, S. Betty
    Um, Suzane L.
    Peek, Victoria L.
    Stephens, Jennifer R.
    Zeng, Wei
    Konicek, Bruce W.
    Liu, Ling
    Manro, Jason R.
    Wacheck, Volker
    Walgren, Richard A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 536 - 544
  • [24] DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
    Davies, Kurtis D.
    Lomboy, Aprille
    Lawrence, Carolyn A.
    Yourshaw, Michael
    Bocsi, Gregary T.
    Camidge, D. Ross
    Aisner, Dara L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 737 - 741
  • [25] Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
    Cortot, Alexis
    Le, Xiuning
    Smit, Egbert
    Viteri, Santiago
    Kato, Terufumi
    Sakai, Hiroshi
    Park, Keunchil
    Camidge, D. Ross
    Berghoff, Karin
    Vlassak, Soetkin
    Paik, Paul K.
    CLINICAL LUNG CANCER, 2022, 23 (03) : 195 - 207
  • [26] Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
    Brazel, Danielle
    Zhang, Shannon
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 33 - 45
  • [27] Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Zhang, Eric W.
    Lennerz, Jochen K.
    Heist, Rebecca S.
    CANCERS, 2019, 11 (12)
  • [28] Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer
    Xia, Yang
    Jin, Rui
    Li, Miao
    Lan, Fen
    Zhu, Hao
    Yu, Yinghui
    Miao, Da
    Wang, Qiyuan
    Zhou, Yi
    Selvaggi, Giovanni
    Ying, Songmin
    Zhang, Jianjun
    Shen, Huahao
    Le, Xiuning
    Li, Wen
    CANCER LETTERS, 2023, 561
  • [29] Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models
    Xu, Yunhua
    Gu, Linping
    Li, Yingqi
    Zhao, Ruiying
    Jian, Hong
    Xie, Wenhui
    Liu, Liu
    Wu, Huiwen
    Ren, Fang
    Han, Yuchen
    Lu, Shun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
    Rotow, Julia K.
    Gui, Philippe
    Wu, Wei
    Raymond, Victoria M.
    Lanman, Richard B.
    Kaye, Frederic J.
    Peled, Nir
    de la Cruz, Ferran Fece
    Nadres, Brandon
    Corcoran, Ryan B.
    Yeh, Iwei
    Bastian, Boris C.
    Starostik, Petr
    Newsom, Kimberly
    Olivas, Victor R.
    Wolff, Alexander M.
    Fraser, James S.
    Collisson, Eric A.
    McCoach, Caroline E.
    Camidge, D. Ross
    Pacheco, Jose
    Bazhenova, Lyudmila
    Li, Tianhong
    Bivona, Trever G.
    Blakely, Collin M.
    CLINICAL CANCER RESEARCH, 2020, 26 (02) : 439 - 449
12345